Informa PLC
09 October 2006
9 October 2006
Acquisition of LEA further strengthens US portfolio
Informa plc, the leading global information specialist, announced today that its
Academic & Scientific division has agreed to acquire, subject to the receipt of
regulatory clearances, Lawrence Erlbaum Associates, Inc., Publishers (LEA) of
New Jersey for a consideration of $71 million (£38m).
LEA which publishes more than 100 academic journal titles and 200 new books a
year under the imprints of Lawrence Erlbaum Associates and The Analytic Press is
well known for its extensive range of titles in the fields of behavioural
science and education.
Informa has annual sales in excess of £200million in the academic and scientific
publishing sector. LEA's sales for the year ended 31 December 2005 were $21m
(£11.5m).
Enquiries:
Informa plc Tel: 020 7017 5000
Peter Rigby, Chief Executive
David Gilbertson, Group Managing Director
Tony Foye, Finance Director
Susanna Kempe, Chief Marketing Officer
Financial Dynamics Tel: 020 7831 3113
Charles Palmer / Darrel Connell
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.